Beximco Pharma starts exports to Hong Kong
Wednesday, 29 August 2007
FE Report
Bangladesh's largest drug exporter Beximco Pharmaceuticals Ltd. (BPL) has started medicine exports to Hong Kong, one of the most stringently regulated markets in the Asia-Pacific region, a company statement said Tuesday.
The first export consignment included seven products, namely Azmasol® (Salbutamol) Inhaler, Alendon® (Alendronate Sodium 10 mg) Tablet, Alendon®-70 (Alendronate Sodium 70 mg) Tablet, Amdocal® 5 (Amlodipine 5 mg) Tablet, Amdocal® 10 (Amlodipine 10 mg) Tablet, Exovate® N (Combination of Neomycin, Nystatin and Clobetasol) Cream and Terbex® (Terbinafine) Cream.
The products will be distributed by a highly acclaimed pharmaceutical marketing company, which has a long-standing partnership with renowned US and European pharmaceutical manufacturers, company officials said.
BPL has registered 15 products in Hong Kong so far and 12 others are expected to receive marketing authorisation soon.
Nazmul Hassan, CEO of Beximco Pharma said:
"In our global expansion programme, Asia-Pacific region is strategically important for us and Hong Kong being one of the stringently regulated markets in this region, achieving success in registering and exporting our products there is a major strategic breakthrough for BPL. I see this as a clear testimony not only to our excellent product quality, but also to our capabilities to meet regulatory requirements of different markets and I hope this will stir our growth in this region in the coming years."
Bangladesh's largest drug exporter Beximco Pharmaceuticals Ltd. (BPL) has started medicine exports to Hong Kong, one of the most stringently regulated markets in the Asia-Pacific region, a company statement said Tuesday.
The first export consignment included seven products, namely Azmasol® (Salbutamol) Inhaler, Alendon® (Alendronate Sodium 10 mg) Tablet, Alendon®-70 (Alendronate Sodium 70 mg) Tablet, Amdocal® 5 (Amlodipine 5 mg) Tablet, Amdocal® 10 (Amlodipine 10 mg) Tablet, Exovate® N (Combination of Neomycin, Nystatin and Clobetasol) Cream and Terbex® (Terbinafine) Cream.
The products will be distributed by a highly acclaimed pharmaceutical marketing company, which has a long-standing partnership with renowned US and European pharmaceutical manufacturers, company officials said.
BPL has registered 15 products in Hong Kong so far and 12 others are expected to receive marketing authorisation soon.
Nazmul Hassan, CEO of Beximco Pharma said:
"In our global expansion programme, Asia-Pacific region is strategically important for us and Hong Kong being one of the stringently regulated markets in this region, achieving success in registering and exporting our products there is a major strategic breakthrough for BPL. I see this as a clear testimony not only to our excellent product quality, but also to our capabilities to meet regulatory requirements of different markets and I hope this will stir our growth in this region in the coming years."